Document Classification

Section Type: METHODS

Text: Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0. 75 Gy on day -12), carmustine 300 mg/m (2) (day -6), etoposide 100 mg/m (2) twice daily (days -5 to -2), cytarabine 100 mg/m (2) twice daily (days -5 to -2), and melphalan 140 mg/m (2) (day -1 ; B-BEAM) or rituximab 375 mg/m (2) on days -19 and -12 and the same chemotherapy regimen (R-BEAM).